1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Astellas Pharma Inc.

Astellas Pharma Inc.

ALPMY
Astellas Pharma Inc.US flagOther OTC
15.05
USD
-0.43
- -
26.98BMarket Cap
Astellas Pharma Inc.
ALPMY
(Other OTC)

Recent

price

15.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
413.12
104.94
342.07
507.41
564.61
636.06
621.89
640.49
676.2
693.34
672.83
700.74
834.4
894.27
1,068.21
1,194.37
466.74
Revenue per Share
29.3
8.47
32.21
40.45
61.5
89.75
103.69
81.11
115.05
104.15
64.93
67.08
54.24
9.5
28.35
162.77
-10.47
Basic EPS, GAAP
21.62
11.75
25.91
70.38
48.22
90.64
88.64
134.14
106.89
76.81
123.53
97.85
131.44
50.18
76.63
265.5
46.9
Free Cash Flow per Basic Share
25
6.25
20.92
26.11
28.13
32.26
33.25
35.28
37.3
39.2
41.01
46.08
55.14
65.05
72.05
75.99
35.01
Dividend per Share
442.2
480.87
520.69
568.53
600.93
592.57
615.89
641.38
667.29
694.03
748.03
799.26
839.26
890.07
845.25
1,020.96
854.73
Book Value per Share
283.19
283.67
321.98
390.65
403.87
362.28
346.67
322.84
319.66
154.05
243.21
292.19
343.42
-154.22
-14.34
218.22
-106.82
Tangible Book Value per Share
2,309
9,237
2,870
2,247
2,209
2,158
2,109
2,030
1,932
1,876
1,857
1,850
1,820
1,793
1,790
1,791
1,792
Basic Weighted Avg Shares
953,947
969,387
981,899
1,139,909
1,247,259
1,372,706
1,311,665
1,300,316
1,306,348
1,300,843
1,249,528
1,296,163
1,518,619
1,603,672
1,912,323
2,139,245
836,534
Sales/Revenue/Turnover
12.49
13.57
12.27
10.12
14.87
18.23
20.03
16.59
18.8
18.88
10.85
10.1
8.66
1.18
2.1
17.77
-3.23
Operating Margin (%)
65,673
65,500
51,167
64,304
65,474
69,188
63,791
64,863
63,458
66,396
72,652
79,684
105,738
157,840
199,132
194,594
95,627
Depreciation Expense
67,650
78,230
92,464
90,874
135,856
193,687
218,701
164,679
222,265
195,411
120,589
124,086
98,714
17,045
50,747
291,535
-18,765
Net Income, GAAP
34.63
38.44
27.26
25.5
28.38
26.01
22.38
24.5
10.73
20.35
17.02
20.91
25.42
31.74
- -
22.57
16.17
Effective Tax Rate (%)
7.09
8.07
9.42
7.97
10.89
14.11
16.67
12.66
17.01
15.02
9.65
9.57
6.5
1.06
2.65
13.63
-2.24
Profit Margin (%)
413,506
394,440
447,818
572,604
545,068
484,178
476,809
423,999
359,494
68,806
280,216
235,943
323,920
-90,995
139,739
203,522
109,654
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
50,000
447,738
564,893
320,000
620,240
LT Debt
1,021,096
1,125,157
1,174,606
1,268,476
1,317,916
1,259,209
1,271,810
1,268,289
1,258,396
1,289,168
1,386,115
1,460,308
1,507,954
1,595,988
1,513,255
1,830,884
1,529,842
Total Equity
7.35
7.39
7.51
6.97
10.16
14.18
15.92
12.64
17.06
15.23
8.37
7.18
6.27
0.62
- -
12.15
- -
Return on Invested Capital (%)
6.53
7.3
8.16
7.54
10.68
15.12
17.4
13.07
17.69
15.53
9.16
8.99
6.81
1.22
- -
12.76
0.45
Return on Capital (%)
6.52
7.29
8.04
7.44
10.51
15.03
17.28
12.97
17.59
15.34
9.02
8.72
6.65
1.1
3.26
17.45
-1.18
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
472,278
- -
307,257
LT Borrowings
447,738
- -
620,240
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,793
1,793
1,790
Market Capitalization
2,919,255
2,846,101
2,953,514

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
1,194,730
- -
1,203,009
Cash, Cash Equivalents & STI
364,471
- -
329,257
Accounts Receivable, Net
534,985
- -
558,269
Inventories
248,738
- -
260,214
Total Current Liabilities
1,285,725
- -
1,093,355
Payables & Accruals
- -
- -
- -
ST Debt
472,278
- -
307,257
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.02%
6.05%
20.99%
Free Cash Flow
29.38%
49.56%
246.65%
Net Income, GAAP
54.47%
114.39%
474.49%
Sales/Revenue/Turnover
4.84%
11.52%
11.87%
Total Cash Common Dividend
7.11%
12.4%
5.51%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1,912,323
2026
- -
- -
- -
- -
2,139,245
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
28.35
2026
- -
- -
- -
- -
162.77
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
72.05
2026
- -
- -
- -
- -
75.99
2027
- -
- -
- -
- -
- -
Similar Companies
Bristol-Myers Squibb Company (BRM.DE)
Eli Lilly and Company (LLY.SW)
Roche Holding AG (RHHBY)
JCR Pharmaceuticals Co., Ltd. (4552.T)
Aurora Optoelectronics Co.,Ltd. (600666.SS)
Scilex Holding Company (SCLX)
Business
Astellas Pharma Inc. (ALPMY) develops, manufactures, markets, and distributes pharmaceutical products worldwide, with a focus on oncology, rare diseases, immunology, nephrology, urology, ophthalmology, and women's health; core brands include XTANDI and PADCEV for prostate and urothelial cancers, XOSPATA for acute myeloid leukemia, VYLOY (zolbetuximab) for gastric cancer, VEOZAH (fezolinetant) for menopause symptoms, IZERVAY (avacincaptad pegol) for geographic atrophy, EVRENZO for anemia in chronic kidney disease, BETANIS/Myrabetriq/BETMIGA for overactive bladder, and PROGRAF/Advagraf immunosuppressants for transplantation. Headquartered in Tokyo, Japan, and founded in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, the company operates in over 70 countries across Japan, the Americas, Europe, Middle East, Africa, and Asia-Oceania, employing more than 13,500 people and reporting fiscal 2024 revenue of ¥1,912.3 billion ($12.58 billion). Recent developments include a May 2025 licensing deal with Evopoint Biosciences for a CLDN18.2-targeting antibody-drug conjugate worth up to $1.34 billion, a 2024 TCR-T cell therapy collaboration with Poseida Therapeutics, a $50 million option agreement with AviadoBio in October 2024 for a frontotemporal dementia gene therapy, strategic investments in later-stage assets amid pipeline reprioritization, and ongoing partnerships such as with Vivtex Corporation for oral formulation technology and Roche Diabetes Care Japan for diabetes management solutions.

Company News

Company News APIChatGPT

  • zacks.com

    Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

  • defenseworld.net

    Kyowa Kirin (OTCMKTS:KYKOF) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Analysis

  • zacks.com

    New Strong Sell Stocks for August 19th

  • seekingalpha.com

    Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors

  • zacks.com

    New Strong Sell Stocks for August 6th

  • zacks.com

    Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?

  • zacks.com

    Is Astellas Pharma (ALPMY) Stock Undervalued Right Now?

  • zacks.com

    Is Astellas Pharma (ALPMY) a Great Value Stock Right Now?

  • zacks.com

    Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?

  • seekingalpha.com

    Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 Transcript

  • gurufocus.com

    Astellas Targets ¥4.3 Trillion Profit Push As Xtandi Pressure Builds

  • zacks.com

    MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer

  • zacks.com

    Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?

  • seekingalpha.com

    Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript

  • zacks.com

    Are Medical Stocks Lagging Arcellx (ACLX) This Year?

  • zacks.com

    Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?

  • seekingalpha.com

    Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript

  • zacks.com

    Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

  • seekingalpha.com

    Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish

  • reuters.com

    Astellas collaborates with Vir to develop its experimental prostate cancer drug